Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLRX 
Salarius Pharmaceuticals Inc (SLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.82% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.77M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 1 | Beta 0.5 | 52 Weeks Range 4.50 - 55.05 | Updated Date 09/16/2025 |
52 Weeks Range 4.50 - 55.05 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -143.52% | Return on Equity (TTM) -660.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1009861 | Price to Sales(TTM) 18.12 |
Enterprise Value 1009861 | Price to Sales(TTM) 18.12 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 1.52 | Shares Outstanding 509643 | Shares Floating 33932 |
Shares Outstanding 509643 | Shares Floating 33932 | ||
Percent Insiders 0.47 | Percent Institutions 2.51 |
Upturn AI SWOT
Salarius Pharmaceuticals Inc
Company Overview
History and Background
Salarius Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company founded in 2011. It focuses on developing therapies for cancers, particularly those with unmet needs.
Core Business Areas
- Drug Development: Focuses on the discovery and development of novel treatments for cancers using epigenetic approaches.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and business management. The company has a typical organizational structure with departments dedicated to research, clinical development, and operations.
Top Products and Market Share
Key Offerings
- Seclidemstat: Seclidemstat is Salarius's lead investigational product, a reversible LSD1 inhibitor. It's being developed for Ewing sarcoma and other cancers. As a development stage product, no market share or revenue exists currently. Competitors in Ewing Sarcoma and related cancers include larger pharmaceutical companies developing targeted therapies and chemotherapies. Examples include major oncology pharmaceutical companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for various diseases. There is significant investment in oncology drug development.
Positioning
Salarius is positioned as a company focused on epigenetic approaches to cancer treatment, targeting specific unmet needs within the oncology space.
Total Addressable Market (TAM)
The TAM for cancer therapies is substantial, estimated to be in the hundreds of billions of dollars globally. Salarius is targeting specific niche markets within oncology, aiming to capture a portion of this large TAM with its novel approach.
Upturn SWOT Analysis
Strengths
- Novel epigenetic approach
- Experienced leadership team
- Focus on unmet needs in oncology
- Lead drug candidate with potential
Weaknesses
- Limited financial resources
- Single lead product
- High risk associated with drug development
- Reliance on clinical trial success
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- Larger Oncology Pharmaceuticals (No specific ticker provided as they compete across therapeutic areas)
Competitive Landscape
Salarius's advantage lies in its novel approach and focus on specific cancer subtypes. Its disadvantage is its limited resources compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in pre-clinical and clinical development programs.
Future Projections: Future growth is dependent on the successful completion of clinical trials and subsequent commercialization of its drug candidates. Analyst estimates will vary significantly based on trial data.
Recent Initiatives: Recent initiatives likely include enrollment in ongoing clinical trials and exploration of new therapeutic targets.
Summary
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing epigenetic therapies for cancer. Its success hinges on the positive outcomes of its clinical trials, particularly for Seclidemstat. The company faces significant challenges due to its limited financial resources and the high risk associated with drug development. However, its novel approach and focus on unmet needs present potential opportunities for growth and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Salarius Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2015-01-29 | Acting CEO, Executive VP of Finance & CFO Mr. Mark J. Rosenblum CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.salariuspharma.com |
Full time employees 2 | Website https://www.salariuspharma.com | ||
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.